American Journal of Hematology

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. 2023

Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.  98:11-22. 2023

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.  97:1170-1177. 2022

Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease.  97:E318-E320. 2022

Validation of single-gene noninvasive prenatal testing for sickle cell disease.  97:E270-E273. 2022

Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.  97:603-612. 2022

Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma.  97:E153-E155. 2022

Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim–Chester disease.  97:293-302. 2022

Bispecific T-cell engagers for treatment of multiple myeloma 2022

A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series.  96:E464-E468. 2021

Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival.  96:1604-1610. 2021

Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.  96:E396-E398. 2021

Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study.  96:E265-E268. 2021

Hyperuricemia and abnormal nocturnal dipping impact glomerular filtration rate in patients with sickle cell anemia.  96:E143-E146. 2021

Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.  96:E146-E150. 2021

New regimens and directions in the management of newly diagnosed multiple myeloma.  96:367-378. 2021

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.  96:E5-E8. 2021

Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.  95:E239-E242. 2020

Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.  95:662-671. 2020

Hapticophagia: Tactile chew cravings in iron deficiency anemia.  95:E107-E108. 2020

Hemoglobin levels and coronary heart disease risk by age, race, and sex in the reasons for geographic and racial differences in stroke study (REGARDS).  95:258-266. 2020

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.  95:18-27. 2020

Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era.  94:1335-1343. 2019

A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.  94:E299-E301. 2019

Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.  94:417-423. 2019

Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.  94:200-208. 2019

Fat embolism syndrome due to bone marrow necrosis in patients with hemoglobinopathies: A life-threatening complication mimicking thrombotic thrombocytopenic purpura.  94:E64-E66. 2019

Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.  94:55-61. 2019

Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.  94:E27-E29. 2019

The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease.  93:E391-E395. 2018

Opioid utilization patterns in United States individuals with sickle cell disease.  93:E345-E347. 2018

Incomplete implementation of guideline-based stroke prevention therapy in sickle cell disease.  93:E222-E224. 2018

Acute kidney injury during parvovirus B19-induced transient aplastic crisis in sickle cell disease.  93:E198-E200. 2018

Visualization of the bone marrow biopsy needle track.  93:E60-E61. 2018

Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.  93:238-245. 2018

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.  93:E49-E52. 2018

Rare complication of treated immune thrombocytopenia.  92:1262-1266. 2017

Sickle cells produce functional immune modulators and cytotoxics.  92:981-988. 2017

A follow-up on desiderosmia (olfactory craving), a novel symptom associated with iron deficiency anemia.  92:E546. 2017

Early mortality and overall survival of acute myeloid leukemia based on facility type.  92:764-771. 2017

High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia.  92:E164-E166. 2017

The association of histologic grade with acute graft-versus-host disease response and outcomes.  92:683-688. 2017

Desiderosmia (olfactory craving): A novel symptom associated with iron deficiency anemia.  92:E93-E94. 2017

Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.  92:E81-E83. 2017

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.  92:161-170. 2017

Transcranial doppler re-screening of subjects who participated in STOP and STOP II.  91:1191-1194. 2016

Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.  91:1044-1051. 2016

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.  91:101-108. 2016

Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis.  90:1052-1054. 2015

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission.  90:242-249. 2015

Seasonal and regional variation of thrombotic thrombocytopenic purpura in the United States: Insights from the Nationwide Inpatient Sample.  90:E24. 2015

Peering into the future: Hepcidin testing.  88:976-978. 2013

Novel G377S (c.1246G>T) mutation associated with Gaucher disease type 1.  88:922-923. 2013

The isolated prolonged PTT.  88:82-85. 2013

Multiorgan failure and bone marrow necrosis in three adults with sickle cell-β ⁺-thalassemia.  87:621-624. 2012

Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.  86:699-701. 2011

High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa.  86:554-558. 2011

Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.  86:430-432. 2011

Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.  85:627-629. 2010

Heritability of serum iron measures in the hemochromatosis and iron overload screening (HEIRS) family study.  85:101-105. 2010

HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants.  84:710-714. 2009

Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population.  83:618-626. 2008

Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.  83:593-595. 2008

Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening.  83:126-132. 2008

Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study.  82:898-905. 2007

Refractory thrombocytopenia and positive platelet crossmatches without HLA or platelet-specific antibodies.  82:175-176. 2007

Use of breath carbon monoxide measurements to assess erythrocyte survival in subjets with chronic diseases.  81:432-438. 2006

Autoimmune hemolytic anemia in an infant with giant cell hepatitis..  81:199-201. 2006

Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.  81:199-201. 2006

Acute transient leukopenia as a sign of TRALI [5].  80:90-91. 2005

Scurvy: An often forgotten cause of bleeding [2].  74:85-87. 2003

Inflammatory mediators promote strong sickle cell adherence to endothelium under venular flow conditions.  73:215-224. 2003

Hairy cell leukemia with concurrent cryptococcus infection.  72:223-224. 2003

Baseline levels of plasma endothelin-1 (ET-1) and changes during transfusion in thalassemic patients.  70:260-262. 2002

Sickle erythrocyte adherence to endothelium at low shear: Role of shear stress in propagation of vaso-occlusion.  70:216-227. 2002

Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura.  69:228-231. 2002

Non-anemic homozygous β thalassemia in an african-american family: Association of high fetal hemoglobin levels with β thalassemia alleles.  68:43-50. 2001

Molecular basis for Rh(null) syndrome: Identification of three new missense mutations in the Rh50 glycoprotein gene.  62:25-32. 1999

Molecular basis for Rh(null) syndrome: identification of three new missense mutations in the Rh50 glycoprotein gene..  62:25-32. 1999

BFU-E Colony Growth in Response to Hydroxyurea: Correlation between In Vitro and In Vivo Fetal Hemoglobin Induction.  56:252-258. 1997

Inhibition of plasma-mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD-containing peptides.  53:92-98. 1996

Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: An aid in assessing marrow recovery.  46:319-324. 1994

Unusually large von willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells.  42:284-292. 1993

Regulation of Tissue Plasminogen Activator in Sickle Cell Anemia.  35:167-170. 1990

Protein S and C antigen levels in proteinuric patients: Dependence on type of glomerular pathology.  31:96-101. 1989

Totally implantable intravenous catheters in the management of sickle cell anemia..  29:134-138. 1988

In vitro effects of gammaglobulin (IgG) on human monocyte Fc receptor function. I. Effect on monocyte membrane‐associated IgG and Fc receptor‐dependent binding of antibody‐coated platelets.  23:197-207. 1986